Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013-2018.

Chintan V DaveSebastian SchneeweissDeborah J WexlerGregory BrillElisabetta Patorno

Published in: Diabetes care (2020)

For SGLT2i, shifts in preference for empagliflozin followed changes in drug labels and guidelines, while for GLP-1RA, other factors such as price or ease of administration may have led to a preference for dulaglutide over liraglutide.

Keyphrases

primary care
adverse drug
rheumatoid arthritis
clinical practice
decision making
emergency department
ankylosing spondylitis
systemic lupus erythematosus
electronic health record
light emitting